Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant
Status:
Recruiting
Trial end date:
2026-04-23
Target enrollment:
Participant gender:
Summary
Donor Lymphocyte Infusion (DLI) following salvage chemotherapy is the one of the most widely
used treatment approaches in patients who relapse after allogeneic hematopoietic cell
transplant (allo-HCT). However, the complete remission (CR) rates and long term survival
remain very poor in these patients and, therefore, there is an unmet need to develop more
effective treatment approaches in patients who relapse after allo-HCT.
Based on the initial promising results with our ongoing cytokine-induced memory-like (CIML)
natural killer (NK) cell trial, the investigators hypothesize that combining the CIML NK
cells with DLI approach will significantly enhance the graft versus leukemia and therefore
potentially provide potentially curative therapy for these patients with otherwise extremely
poor prognosis. Combining CIML NK cells with the DLI platform will also potentially allow
these adoptively transferred cells to persist for longer duration as they should not be
rejected by donor T cells as the CIML NK cells are derived from the same donor. The use of
CIML NK cells is unlikely to lead to excessive graft versus host disease (GVHD) as previous
studies have not been associated with excessive GVHD rates.